Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6320220B2 - - Google Patents
[go: Go Back, main page]

JPS6320220B2 - - Google Patents

Info

Publication number
JPS6320220B2
JPS6320220B2 JP54163954A JP16395479A JPS6320220B2 JP S6320220 B2 JPS6320220 B2 JP S6320220B2 JP 54163954 A JP54163954 A JP 54163954A JP 16395479 A JP16395479 A JP 16395479A JP S6320220 B2 JPS6320220 B2 JP S6320220B2
Authority
JP
Japan
Prior art keywords
lysine
filtrate
methanol
carbon dioxide
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54163954A
Other languages
Japanese (ja)
Other versions
JPS5587753A (en
Inventor
Buryu Jan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS5587753A publication Critical patent/JPS5587753A/en
Publication of JPS6320220B2 publication Critical patent/JPS6320220B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/40Effervescence-generating compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

【発明の詳細な説明】 本発明はL―リシンカルバマートを製造する新
規で経済的な方法に係わるものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a new and economical process for producing L-lysine carbamate.

L―リシンカルバマートは、例えば沸騰性飲料
や、沸騰性カシエー又は錠剤の如き沸騰性薬剤組
成物を製造するのに用いられる沸騰性混合物の成
分として特に使用される。とりわけ、アルカリ性
イオンを全く含有していないか、ほんの僅かにし
か含有していない沸騰性薬剤組成物に適用される
ことが多い。この型の薬剤組成物では人体内にア
ルカリ性イオンが蓄積される危険性が全くなく、
ナトリウムを含まない規定食を摂つている患者に
でも用いることができる。
L-lysine carbamate is particularly used as a component of effervescent mixtures used to produce effervescent pharmaceutical compositions such as effervescent beverages, effervescent cassiers or tablets. In particular, it is often applied to effervescent drug compositions that contain no or only small amounts of alkaline ions. With this type of pharmaceutical composition, there is no risk of alkaline ions accumulating in the human body;
It can also be used in patients on a sodium-free diet.

L―リシンカルバマートを用いれば、更に、緩
衝媒体が含まれているので胃の耐薬性が非常に優
れたものになり、ほとんどすぐに血液中に吸収さ
れる。
L-lysine carbamate also has very good gastric tolerance due to the inclusion of a buffering medium and is absorbed almost immediately into the blood.

本発明により、本発明者は出発原料として飼料
等級のL―リシンモノヒドロクロリドを使用する
ことのできる、従つて比較的安価な、L―リシン
カルバマートの新規な製造方法を発見した。
With the present invention, the inventors have discovered a new process for the production of L-lysine carbamate, which allows the use of feed-grade L-lysine monohydrochloride as starting material and is therefore relatively inexpensive.

このL―リシンモノヒドロクロリドは第一に水
溶液としてカーボンブラツクにより脱色処理さ
れ、このカーボンブラツクはその後例えば濾過法
等により除去される。
This L-lysine monohydrochloride is first decolorized using carbon black as an aqueous solution, and the carbon black is then removed by, for example, a filtration method.

第二の段階ではL―リシンモノヒドロクロリド
をKOHやNaOHの如き塩基で処理して公知の方
法(例えばスピン乾燥)で生じた塩、塩化カリウ
ム又は塩化ナトリウム等を除去し、次いで溶剤、
好ましくはメタノールを添加する。
In the second step, the L-lysine monohydrochloride is treated with a base such as KOH or NaOH to remove the resulting salts, potassium chloride or sodium chloride, etc. by known methods (e.g. spin drying), and then a solvent,
Preferably methanol is added.

本発明の第三の段階では、第二段階で得られた
濾液が二酸化炭素(又はドライアイス)と反応さ
せる処理がされ、所望の生産物である生成された
沈殿物が回収される。
In the third step of the present invention, the filtrate obtained in the second step is treated to react with carbon dioxide (or dry ice) and the resulting precipitate, which is the desired product, is recovered.

このようにして得られたL―リシンカルバマー
トは白色の結晶状粉末形状を成していて、この生
成物は水に対して高度の可溶性を有しているがメ
タノールに不溶であるため、上記沈殿物をメタノ
ールで洗浄することができる。
The L-lysine carbamate thus obtained is in the form of a white crystalline powder, and this product is highly soluble in water but insoluble in methanol, as described above. The precipitate can be washed with methanol.

本発明を限定するものではないが、本発明者
は、1モルのL―リシンと1モルのCO2との組合
せから生成されるL―リシンカルバマートを更に
1モルのL―リシンにより安定させることができ
ると考える。
Without limiting the invention, the inventors have determined that the L-lysine carbamate produced from the combination of 1 mole of L-lysine and 1 mole of CO2 is further stabilized by 1 mole of L-lysine. I think it is possible.

これは分析の結果により確認することができ
る。次の実施例は本発明を説明するものであるが
本発明の範囲を限定するものではない。
This can be confirmed by the results of the analysis. The following examples illustrate the invention but do not limit the scope of the invention.

実施例 1 300gの「飼料等級」のL―リシンモノヒドロ
クロリド(すなわち動物の飼料等級)(滴定濃度
>98%)を300cm3の水に50℃から60℃の間の温度
で溶解させる。
Example 1 300 g of "feed grade" L-lysine monohydrochloride (ie animal feed grade) (titer >98%) are dissolved in 300 cm 3 of water at a temperature between 50°C and 60°C.

この混合物を6gの脱色カーボンブラツクと共
に60℃で15分間撹拌する。
This mixture is stirred with 6 g of decolorized carbon black for 15 minutes at 60°C.

次いでこれを紙により濾過する。 This is then filtered through paper.

撹拌しながら110gのKOHを約40℃で徐々に加
え、この混合物を室温まで冷却して次いで1時間
撹拌する。1500cm3のメタノールを徐々に加えて混
合物を2時間半撹拌し、生成された塩化カリウム
をスピン乾燥させる。
110 g of KOH are added slowly at about 40° C. while stirring, the mixture is cooled to room temperature and then stirred for 1 hour. 1500 cm 3 of methanol are gradually added and the mixture is stirred for 2.5 hours and the potassium chloride formed is spun dry.

濾液に60gから80gの二酸化炭素を約1時間か
けて徐々に添加し、混合物を一晩放置し、濾過
し、95%のメタノール中で洗浄して約40℃で乾燥
させる。200gの所望の生成物が得られる。
60 to 80 g of carbon dioxide are slowly added to the filtrate over about 1 hour, the mixture is left overnight, filtered, washed in 95% methanol and dried at about 40°C. 200 g of desired product are obtained.

M.P.249―250℃ 分 析:C13H28N4O6 算定量:C%46.41 H%8.39 N%16.65 O%28.54 測定量:C%46.62 H%8.37 N%28.33 実施例 2 300gの「飼料等級」のL―リシンモノヒドロ
クロリド(滴定濃度>98%)を450cm3の水に30℃
で溶解する。
MP249-250℃ Analysis: C 13 H 28 N 4 O 6 Calculated amount: C%46.41 H%8.39 N%16.65 O%28.54 Measured amount: C%46.62 H%8.37 N%28.33 Example 2 300g of “feed grade” ” L-lysine monohydrochloride (titration concentration >98%) was added to 450 cm 3 of water at 30°C.
Dissolve with.

溶液を6gの脱色カーボンブラツクと共に30℃
で15分間撹拌する。
The solution was incubated at 30°C with 6g of decolorized carbon black.
Stir for 15 minutes.

次いで紙により濾過する。 Then filter through paper.

79gの水酸化ナトリウムを約20℃で徐々に加え
混合物を室温まで冷却して次いで1時間撹拌す
る。次いで2000cm3のメタノールを徐々に加えて混
合物を3時間撹拌し、生成された塩化ナトリウム
をスピン乾燥させる。
79 g of sodium hydroxide are added slowly at about 20° C. and the mixture is cooled to room temperature and then stirred for 1 hour. Then 2000 cm 3 of methanol are gradually added and the mixture is stirred for 3 hours and the sodium chloride formed is spun dry.

約1時間にわたつて60gから80gの二酸化炭素
を濾液に徐々に添加し、混合物を一晩放置して次
いで濾過し、95%のメタノール内で洗浄し、40℃
で乾燥させる。189gの所望の生成物が得られる。
60 to 80 g of carbon dioxide was slowly added to the filtrate over about 1 hour, the mixture was allowed to stand overnight and then filtered, washed in 95% methanol and incubated at 40°C.
Dry with. 189 g of desired product are obtained.

M.P.246―250℃ 分析:C13H28N4O6 算定量:C%46.41 H%8.39
N%16.65 O%28.54 測定量:C%46.23 H%8.43
N%16.67 O%28.29 実施例 3 もはや白色の沈殿物が形成されなくなるまで
CO2を泡立たせる代わりにドライアイスを徐々に
導入することを除いて実施例1と同じ方法を用い
る。次いで混合物を放置して室温まで冷却し、3
時間半撹拌する。生成物を濾過して800cm3のメタ
ノール内で洗浄すると、192gの所望の生成物が
得られる。
MP246-250℃ Analysis: C 13 H 28 N 4 O 6 Calculated amount: C%46.41 H%8.39
N%16.65 O%28.54 Measured amount: C%46.23 H%8.43
N% 16.67 O% 28.29 Example 3 Until no more white precipitate is formed
The same method as Example 1 is used except that instead of bubbling CO 2 dry ice is gradually introduced. The mixture was then allowed to cool to room temperature and 3
Stir for half an hour. The product is filtered and washed in 800 cm 3 of methanol to give 192 g of desired product.

M.P.247―250℃ 参考例 1 アセチルサリチル酸を含有していてアルカリ性
イオンを含んでいない沸騰性錠剤 次の比率で沸騰性混合物を形成する: アセチルサリチル酸 0.500g L―リシンカルバマート 16g クエン酸 0.4g 上記の値はアセチルサリチル酸0.5gで従来の方
法で投薬する錠剤の場合に関するものである。
MP247-250℃ Reference Example 1 Effervescent tablet containing acetylsalicylic acid and no alkaline ions Form an effervescent mixture in the following proportions: Acetylsalicylic acid 0.500g L-lysine carbamate 16g Citric acid 0.4g of the above The values relate to tablets dosed in the conventional manner with 0.5 g of acetylsalicylic acid.

参考例 2 次の比率に従つて沸騰性飲料用の沸騰性組成物
を形成する: 砂糖 17g L―リシンカルバマート 1.4g クエン酸 2.7g この組成物には粉末形状のフルーツ抽出物で風
味を添えることができる。オレンジフレーバーを
用いる場合には必要に応じてビタミンCを添加し
ても良い。
Reference Example 2 A effervescent composition for an effervescent beverage is formed according to the following proportions: Sugar 17g L-lysine carbamate 1.4g Citric acid 2.7g The composition is flavored with fruit extract in powdered form. be able to. When using orange flavor, vitamin C may be added as necessary.

参考例 3 0.5gのリンを投与する沸騰性錠剤の製造 例えば次の式を用いることができる: L―リシンカルバマート 1.4g リン酸グリココル 1.397g 無水マグネシウム―塩基リン酸塩 0.881g 実施例4及び6の錠剤は本発明の分野の当業者
に公知の方法で製造され、成分を分離乾燥、ふる
い分け、混合して錠剤に成形される。
Reference Example 3 Manufacture of effervescent tablets for administering 0.5 g of phosphorus For example, the following formula can be used: L-lysine carbamate 1.4 g Glycocol phosphate 1.397 g Anhydrous magnesium-base phosphate 0.881 g Example 4 and The tablets of No. 6 are manufactured by methods known to those skilled in the art of the present invention, and the ingredients are separated, dried, sieved, mixed and formed into tablets.

治療上の効果、投薬量及び方法もまた公知であ
る。
Therapeutic effects, dosages and methods are also known.

Claims (1)

【特許請求の範囲】 1 滴定濃度が98%以上の『飼料等級』L―リシ
ンモノヒドロクロリド水溶液を、撹拌しながらカ
ーボンブラツクで脱色処理する段階と、紙類によ
り濾過する段階と、濾液に強い塩基を添加し、次
いでL―リシン塩基を含むメタノール水溶液を生
成するためにメタノールを添加し、濾過する段階
と、L―リシン塩基をもつメタノール水溶液から
成る濾液を二酸化炭素と反応させて処理する段階
と、濾過し、沈澱物をメタノールで洗浄して回収
する段階とを含むL―リシンカルバマートの製造
方法。 2 添加される強い塩基が水酸化カリウムまたは
水酸化ナトリウムであることを特徴とする特許請
求の範囲第1項記載の方法。 3 二酸化炭素で濾液を処理する段階において、
濾液内で二酸化炭素を泡立てることまたはこの濾
液にドライアイスを徐々に導入することから成る
ことを特徴とする特許請求の範囲第1項記載の方
法。
[Scope of Claims] 1 A step of decolorizing an aqueous solution of "feed grade" L-lysine monohydrochloride with a titration concentration of 98% or more with carbon black while stirring, a step of filtering it through paper, and a step of filtrate-resistant. Adding a base, then adding methanol to produce an aqueous methanol solution containing L-lysine base, and filtering; and treating the filtrate consisting of the aqueous methanol solution containing L-lysine base by reacting it with carbon dioxide. and filtration, washing the precipitate with methanol, and recovering the L-lysine carbamate. 2. Process according to claim 1, characterized in that the strong base added is potassium hydroxide or sodium hydroxide. 3. In the step of treating the filtrate with carbon dioxide,
2. A method as claimed in claim 1, characterized in that it consists of bubbling carbon dioxide into the filtrate or gradually introducing dry ice into the filtrate.
JP16395479A 1978-12-21 1979-12-17 Manufacture of llricincarbamate Granted JPS5587753A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7836011A FR2444665B1 (en) 1978-12-21 1978-12-21 NEW PROCESS FOR THE PREPARATION OF L-LYSINE CARBAMATE

Publications (2)

Publication Number Publication Date
JPS5587753A JPS5587753A (en) 1980-07-02
JPS6320220B2 true JPS6320220B2 (en) 1988-04-26

Family

ID=9216407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16395479A Granted JPS5587753A (en) 1978-12-21 1979-12-17 Manufacture of llricincarbamate

Country Status (9)

Country Link
JP (1) JPS5587753A (en)
BE (1) BE880749A (en)
DE (1) DE2951132A1 (en)
ES (1) ES487158A1 (en)
FR (1) FR2444665B1 (en)
GB (1) GB2037760B (en)
IT (1) IT1119633B (en)
LU (1) LU82007A1 (en)
NL (1) NL7909081A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760138A (en) * 1984-12-13 1988-07-26 Nestec S. A. Carbonating agents and their preparation
US4937083A (en) * 1988-04-12 1990-06-26 Mitsubishi Chemical Industries Limited Feed additive for ruminants
FR3158966A1 (en) 2024-02-07 2025-08-08 Universite Claude Bernard Lyon 1 PROCESS FOR PREPARING A CROSSLINKED COPOLYMER AND ITS USE AS A POROUS MATERIAL

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2215950A2 (en) * 1973-02-01 1974-08-30 Union Pharma Scient Appl Carbonated lysine - as carbonate source in effervescent compositions

Also Published As

Publication number Publication date
IT7969447A0 (en) 1979-12-20
GB2037760A (en) 1980-07-16
BE880749A (en) 1980-06-20
NL7909081A (en) 1980-06-24
JPS5587753A (en) 1980-07-02
FR2444665A1 (en) 1980-07-18
LU82007A1 (en) 1980-07-21
FR2444665B1 (en) 1985-06-28
ES487158A1 (en) 1980-09-16
GB2037760B (en) 1983-05-11
DE2951132C2 (en) 1988-12-22
DE2951132A1 (en) 1980-07-10
IT1119633B (en) 1986-03-10

Similar Documents

Publication Publication Date Title
US3957853A (en) Metformine salt of acetylsalicylic acid
JPS58162262A (en) Dipeptide sweetener-metal complex
US3140978A (en) Pharmaceutical composition containing complex magnesium aluminum silicate
WO2003092730A1 (en) Hydroxycitric acid salt composition and method of making
AU599034B2 (en) Furosemide salts
US5206265A (en) Iron citrate complex, process for its production, and its pharmaceutical
FI57952C (en) PROCEDURE FOR FRAMSTATION OF AV 7- (D-ALPHA-AMINO-1,4-CYCLOHAXADIEN-1-YLACETAMIDO) -DESASETOXICEFALOSPORANSYRA-DIHYDRATE
JPS6320220B2 (en)
JPH02262534A (en) Bismuth-containing composition suitable for treatment and preparation thereof
JPH05238940A (en) Fast-acting medicine having high absorption rate in vivo and its production
JPS62216910A (en) Manufacture of dry carbon dioxide gas generating agent
JPS5865214A (en) Medicine containing n-acyl-l-aspartyltaurine
US2654735A (en) Process for the production of derivatives of 9-polyhydroxyalkylisoalloxazines and products obtained
US2834782A (en) Monocalcium monopiperazine salt of ethylenediaminetetracetic acid
US3751564A (en) Process for preparing scleroprotein-alkyl thiosulfate agents for the care of the hair
Bogert et al. The synthesis of 6-hydroxypiperonylic acid and incidental compounds
US2871158A (en) Laxative syrups containing di-n-octyl sulfosuccinate salts
US676860A (en) Paraämidophenyl-glyoxylic acid and process of making same.
JPS6078560A (en) Enriched nutrient agent free from acid taste
US3041345A (en) Process of preparation of isonicotinyl hydrazones and hydrazides
US3644395A (en) Phenylbutazone-sodium-monoglycerate
US3597234A (en) Novel substituted tetrazole and use thereof
US850111A (en) Bromin derivative of fatty acids.
CN119039184A (en) Creatine ethyl ester carbonate, preparation method thereof and creatine supplement
US2418866A (en) Process for preparing pectinates